TotalSeq™-B0828 anti-human CD307d (FcRL4), 413D12,BioLegend,340215

Additional reported applications (with relevant formats) include: immunoprecipitation and blocking. mAb 413D12 is able to block the binding of FcRL4 to aggregated IgA, IgG3, and IgG4.

Host

Mouse

Reactivity

Human

Application

PG - Quality tested

Platform ID

BAB184423372

BioLegend

Headquarters

8999 BioLegend Way San Diego, CA 92121 United States

Contact

Tel: 1-858-455-9588
Fax: +49 (4131) 7023913

Email:

Product Specifications
Scientific Background

Specifications

NameTotalSeq™-B0828 anti-human CD307d (FcRL4), 413D12
Cat. No.340215
HostMouse
RRIDAB_2888708 (BioLegend Cat. No. 340215)
IsotypeMouse IgG2b, κ
ReactivityHuman
ApplicationPG - Quality tested
ClonalityMonoclonal
Clone Number413D12
Concentration0.5 mg/mL
TargetCD307d
ImmunogenP815 cells transfected with FcRL4
PurityThe antibody was purified by chromatography and conjugated with TotalSeq™-B oligomer under optimal conditions.
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and EDTA
StorageThe antibody solution should be stored undiluted between 2°C and 8°C.Do not freeze.
Regulatory StatusResearch Use Only

Scientific Background

FcRL4 (Fc receptor-like 4) is a 57 kD single pass type I transmembrane protein that exhibits 4 Ig like C2 domains. Also known as ITRA1, IGFP2, and FcRH4, FcRL4 is predominately found on a subset of memory B cells. Activation of FcRL4 contributes to B cell receptor inhibition through activation of the tyrosine kinases SHP-1 and 2. FcRL4's nascent loci is 1q23.1; however, breakpoint mutations are associated with multiple myeloma and non-Hodgkins lymphoma. Increased FcRL4 expression on memory B cells has also been observed in HIV viremic patients. FcRL4 predominately binds aggregated IgA, binds weakly with IgG3 and IgG4, and does not bind IgG1 and IgG2.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.